Tarsus Pharmaceuticals (TARS) investor relations material

Deal rationale and strategic fit

• Acquisition expands presence into retina, a major eye care segment with over 11 million annual intravitreal injections, addressing unmet needs in ocular surface antiseptics for intravitreal injections.

• IRX-101 offers a novel solution to improve patient experience and outcomes, targeting pain and toxicity from current antiseptic practices.

• Builds on proven commercial and clinical capabilities, leveraging success with previous products and a track record of innovation.

• Strategic move expected to support long-term shareholder value creation and strengthen leadership in eye care.

Financial terms and conditions

• Upfront payment of $75 million: $37.5 million in cash and $37.5 million in stock.

• Up to $490 million in approval and commercial milestones, plus low to mid-single digit tiered royalties.

• Acquisition financed from balance sheet; upfront payment expensed in Q3, milestones capitalized and amortized over patent life.

• Estimated cost to approval is $20–30 million.

Synergies and expected cost savings

• Focused commercial model leverages existing infrastructure, with a dedicated sales force less than half the size of current teams.

• Marketing, back office, and conference support synergies expected.

• Leverages established playbook for evidence generation, physician education, and market access.

• IRX-101 complements the existing portfolio and supports future growth.